Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7EVV

Co-crystal Structure of Toxoplasma gondii Prolyl tRNA Synthetase (TgPRS) in complex with JE6 and L-pro

7EVV の概要
エントリーDOI10.2210/pdb7evv/pdb
分子名称Prolyl-tRNA synthetase (ProRS), ~{N}-[4-[(3~{S})-3-cyano-3-cyclopropyl-2-oxidanylidene-pyrrolidin-1-yl]-6-methyl-pyridin-2-yl]-2-phenyl-ethanamide, PROLINE, ... (6 entities in total)
機能のキーワードtoxoplasma gondii, prolyl trna synthetase, inhibitor-bound structural comparison, translation, multi-drug
由来する生物種Toxoplasma gondii
タンパク質・核酸の鎖数1
化学式量合計58698.63
構造登録者
Malhotra, N.,Mishra, S.,Manickam, Y.,Sharma, A. (登録日: 2021-05-22, 公開日: 2022-03-09, 最終更新日: 2023-11-29)
主引用文献Manickam, Y.,Malhotra, N.,Mishra, S.,Babbar, P.,Dusane, A.,Laleu, B.,Bellini, V.,Hakimi, M.A.,Bougdour, A.,Sharma, A.
Double drugging of prolyl-tRNA synthetase provides a new paradigm for anti-infective drug development.
Plos Pathog., 18:e1010363-e1010363, 2022
Cited by
PubMed Abstract: Toxoplasmosis is caused by Toxoplasma gondii and in immunocompromised patients it may lead to seizures, encephalitis or death. The conserved enzyme prolyl-tRNA synthetase (PRS) is a validated druggable target in Toxoplasma gondii but the traditional 'single target-single drug' approach has its caveats. Here, we describe two potent inhibitors namely halofuginone (HFG) and a novel ATP mimetic (L95) that bind to Toxoplasma gondii PRS simultaneously at different neighbouring sites to cover all three of the enzyme substrate subsites. HFG and L95 act as one triple-site inhibitor in tandem and form an unusual ternary complex wherein HFG occupies the 3'-end of tRNA and the L-proline (L-pro) binding sites while L95 occupies the ATP pocket. These inhibitors exhibit nanomolar IC50 and EC50 values independently, and when given together reveal an additive mode of action in parasite inhibition assays. This work validates a novel approach and lays a structural framework for further drug development based on simultaneous targeting of multiple pockets to inhibit druggable proteins.
PubMed: 35333915
DOI: 10.1371/journal.ppat.1010363
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.704 Å)
構造検証レポート
Validation report summary of 7evv
検証レポート(詳細版)ダウンロードをダウンロード

248335

件を2026-01-28に公開中

PDB statisticsPDBj update infoContact PDBjnumon